Flow cytometry revealed that CD8+ T cells were maintained at substantial levels in Group III (31.2 ± 1.5%) and Group IV (21.3 ± 1.0%) through day 70, indicating durable immune memory even after repeated tumor challenge (Figure S5b, Supporting Information). This evidence concerns the gene CD8A and neoplasm.